US 12,290,552 B2
Topical therapeutic formulations
Jeffry Twidwell, Wayzata, MN (US); Joel Buckley, Plymouth, MN (US); and Harold Hoium, Eden Prairie, MN (US)
Assigned to Hybrid Medical, Inc., Eden Prairie, MN (US)
Filed by Hybrid Medical, LLC, Eden Prairie, MN (US)
Filed on Mar. 27, 2023, as Appl. No. 18/126,901.
Application 18/126,901 is a continuation of application No. 14/977,300, filed on Dec. 21, 2015, granted, now 11,622,997.
Application 14/977,300 is a continuation of application No. 13/747,151, filed on Jan. 22, 2013, granted, now 9,333,242.
Claims priority of provisional application 61/588,441, filed on Jan. 19, 2012.
Prior Publication US 2024/0050535 A1, Feb. 15, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/44 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/12 (2006.01); A61K 31/277 (2006.01); A61K 31/40 (2006.01); A61K 31/4418 (2006.01); A61K 31/4422 (2006.01); A61K 31/554 (2006.01); A61K 45/06 (2006.01); A61K 47/24 (2006.01); A61P 17/00 (2006.01); A61P 19/04 (2006.01); C07D 211/90 (2006.01)
CPC A61K 38/446 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/12 (2013.01); A61K 31/277 (2013.01); A61K 31/40 (2013.01); A61K 31/4418 (2013.01); A61K 31/4422 (2013.01); A61K 31/554 (2013.01); A61K 45/06 (2013.01); A61K 47/24 (2013.01); A61P 17/00 (2018.01); A61P 19/04 (2018.01); C07D 211/90 (2013.01); C12Y 115/01001 (2013.01)] 19 Claims
 
1. A composition suitable for topical application to skin comprising 15 wt % to 30 wt. % of a dihydropyridine calcium channel blocker active agent, 0.1 wt. % to 2 wt. % of superoxide dismutase, 60 wt. % to 85 wt. % of emu oil by weight in the total composition and one or more thickening agents, penetration enhancers, or non-superoxide dismutase anti-oxidants.